Skip to main content
. 2019 Feb 12;67(3):779–794. doi: 10.3233/JAD-180766

Fig.1.

Fig.1

Combination therapies in the AD drug development pipeline. 5-HT, 5-hydroxytryptamine (serotonin); Aβ, amyloid-β; AChE1, acetylcholinesterase inhibitor; AD, Alzheimer’s disease; BACE, aspartyl protease β-site amyloid precursor protein cleaving enzyme; GM-CSF, granulocyte-macrophage colony-stimulating factor; MAO, monoamine oxidase; NMDA, N-methyl-D-aspartate; PPAR, peroxisome-proliferator activated receptor; RAGE, receptor for advanced glycation end-products; rTMS, repetitive transcranial magnetic stimulation.